ERBB2 and breast cancer: Furthermore, KDM5-Inh1 treatment in HER2+ BC cells resistant to the HER2-targeting agent trastuzumab reduced proliferation in both sensitive HER2+ BC cells and trastuzumab-resistant HER2+ BC cells.